Examkin

Question

Difficulty: Very hardGynecologic Oncology

A 56-year-old woman, G2P2, comes to the office to discuss the results of her recent cervical cancer screening. She reached menopause 5 years ago and reports no vaginal bleeding, discharge, or pelvic pain. Her medical history includes hypertension and type 2 diabetes mellitus. Her body mass index is 36 kg/m236 \text{ kg/m}^2. Her cervical cytology (Pap test) results show atypical glandular cells (AGC), and human papillomavirus (HPV) testing is positive. A transvaginal ultrasound performed today shows a thin, homogeneous endometrial stripe measuring 3 mm3 \text{ mm} and normal adnexa. Which of the following is the most appropriate next step in management?

  1. Colposcopy, endocervical curettage, and endometrial biopsyAnswer
  2. B
    Colposcopy and endocervical curettage only
  3. C
    Endometrial biopsy only
  4. D
    Repeat cervical cytology and human papillomavirus testing in 1 year
  5. E
    Loop electrosurgical excision procedure

Answer

Colposcopy, endocervical curettage, and endometrial biopsy
The correct answer is colposcopy, endocervical curettage, and endometrial biopsy. A finding of atypical glandular cells (AGC) on cervical cytology is associated with a high risk of significant underlying pathology, including cervical adenocarcinoma in situ, invasive cervical cancer, and endometrial adenocarcinoma. According to clinical guidelines, all women with AGC require evaluation of the cervix and endocervical canal via colposcopy and endocervical curettage (ECC). In addition, endometrial evaluation with an endometrial biopsy is strictly required for women who are 35 years of age or older, as well as for younger women who have risk factors for endometrial cancer (e.g., obesity, chronic anovulation). While a transvaginal ultrasound showing an endometrial stripe of ≤4 mm\leq 4 \text{ mm} is reassuring in patients presenting with isolated postmenopausal bleeding, it is not an acceptable substitute for tissue sampling in a patient with AGC. Therefore, the biopsy must proceed despite the thin endometrial stripe.

Step-by-Step Solution

1
Identify the clinical presentation and abnormal screening test.
The patient is a 56-year-old postmenopausal woman with atypical glandular cells (AGC) on cervical cytology and a positive HPV test.
AGC is a high-risk finding that requires immediate diagnostic workup to rule out significant neoplasia.
2
Determine the potential sources of the atypical glandular cells.
Glandular cells can originate from the endocervical canal or the endometrium.
Because the source could be either, both anatomical regions must be evaluated in high-risk patients.
3
Apply guidelines for the initial management of AGC.
All women with AGC require colposcopy and endocervical curettage (ECC) to evaluate the cervix.
This is standard protocol to evaluate for cervical adenocarcinoma in situ or invasive cancer.
4
Determine if endometrial evaluation is also indicated.
The patient is older than 35 years of age, so she explicitly requires an endometrial biopsy.
Age ≥35\geq 35 or the presence of risk factors for endometrial cancer (like her obesity) are strict indications for adding endometrial sampling to the AGC workup.
5
Evaluate the impact of the transvaginal ultrasound (TVUS) finding.
The 3 mm3 \text{ mm} endometrial stripe does not alter the management plan; the biopsy must still be performed.
While a TVUS of ≤4 mm\leq 4 \text{ mm} has a high negative predictive value for ruling out cancer in isolated postmenopausal bleeding, it is not an accepted substitute for tissue sampling in a patient with an AGC cytology result.

Key Concept

Women aged 35 years and older (or those with risk factors) presenting with atypical glandular cells (AGC) on cervical cytology require immediate evaluation with colposcopy, endocervical curettage, and endometrial biopsy. A thin endometrial stripe on ultrasound cannot substitute for the mandatory endometrial tissue biopsy.
Rate this question

Topics

Gynecologic Oncology

More questions from this topic